Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

Related Keywords

United Kingdom ,Manchester ,Ibrutinib Imbruvica ,Ann Tivey ,International Prognostic Score Index ,University Of Manchester ,Prognostic Score Index ,Ibrutinib ,Mantle Cell Lymphoma ,Cmcl ,Rituximab ,